Preclinical evaluation of targeted therapies in Sdhb-mutated tumors.
Sign Up to like & getrecommendations! Published in 2022 at "Endocrine-related cancer"
DOI: 10.1530/erc-22-0030
Abstract: Therapies for metastatic SDHB-dependent pheochromocytoma and paraganglioma (PPGL) are limited and poorly efficient. New targeted therapies and identification of early non-invasive biomarkers of response are thus urgently needed for these patients. We characterized an in… read more here.
Keywords: preclinical evaluation; targeted therapies; evaluation targeted; therapies sdhb ... See more keywords
Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma
Sign Up to like & getrecommendations! Published in 2020 at "Cancers"
DOI: 10.3390/cancers12020280
Abstract: Succinate dehydrogenase subunit B (SDHB) deficiency frequently occurs in cluster I pheochromocytomas and paragangliomas (PCPGs). SDHB-mutated PCPGs are characterized by alterations in the electron transport chain, metabolic reprogramming of the tricarboxylic cycle, and elevated levels… read more here.
Keywords: sdhb; sdhb mutated; targeting nrf2; nrf2 governed ... See more keywords